On 2026-09-28, UBS raised its VRTX price target to $615 from $585 (+5.1%).
UBS 于 2026-09-28 将 VRTX 目标价上调至 $615，此前为 $585，变动幅度 +5.1%。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
Jefferies raises VRTX target to $640Jefferies 上调目标价 福泰制药 (VRTX) 至 $640
Rating Change · September 23, 2026评级变动 · 2026/9/23
VERTEX PHARMACEUTICALS INC / MA files 8-K Item 5.02 executive-change disclosure福泰制药 (VRTX) 提交 8-K Item 5.02 高管变动披露
SEC Material Disclosure · September 1, 2026SEC 重大披露 · 2026/9/1
VRTX definitive M&A: Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership TeamVertex Pharmaceuticals Incorporated（VRTX）披露确定性并购进展
Material Company Event · September 1, 2026公司公告 · 2026/9/1
